Paper22460880
Drug development: Raise standards for preclinical cancer research.
Begley CG and 1 other. Nature, 2012. Cited by 1,694 papers, by iCite.
Cite this record
ConductScience Library. Drug development: Raise standards for preclinical cancer research. Papers, record 22460880. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22460880
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomedical Research | Major topic |
| Drug Evaluation, Preclinical | Major topic |
| Neoplasms | Major topic |
| Translational Research, Biomedical | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Clinical Trials as Topic | |
| Humans | |
| Mice | |
| Reproducibility of Results | |
| Research Design | |
| Survival Analysis | |
| Treatment Failure |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 22552083 | Preclinical trials: Keep 'reproducibility' in context. | https://conductscience.org/library/papers/22552083 |
Source PubMed
References5
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20531333 | Raising the bar for cancer therapy models. | Nat Biotechnol | 2010 | https://conductscience.org/library/papers/20531333 | PubMed |
| 2 | 20422014 | Do pressures to publish increase scientists' bias? An empirical support from US States Data. | PLoS One | 2010 | https://conductscience.org/library/papers/20422014 | PubMed |
| 3 | 22371130 | Drug development and clinical trials--the path to an approved cancer drug. | Nat Rev Clin Oncol | 2012 | https://conductscience.org/library/papers/22371130 | PubMed |
| 4 | 21448176 | High drug attrition rates--where are we going wrong? | Nat Rev Clin Oncol | 2011 | https://conductscience.org/library/papers/21448176 | PubMed |
| 5 | 21892149 | Believe it or not: how much can we rely on published data on potential drug targets? | Nat Rev Drug Discov | 2011 | https://conductscience.org/library/papers/21892149 | PubMed |
Cited by1,093
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,694 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953410 | Qualitative study reveals perceived barriers and facilitators of preregistration in animal research. | R Soc Open Sci | 2026 | https://conductscience.org/library/papers/42953410 | PubMed |
| 42922903 | Replication and replicability as epistemic opportunity for the humanities: reflections on a Rembrandt attribution case study. | Humanit Soc Sci Commun | 2026 | https://conductscience.org/library/papers/42922903 | PubMed |
| 42910235 | Human Induced Pluripotent Stem Cells in Rare Neurological Disorders: Opportunities and Challenges for Disease Modeling and Drug Discovery. | Stem Cells Int | 2026 | https://conductscience.org/library/papers/42910235 | PubMed |
| 42882581 | Reproducibility in Studies on Dental Restorative Materials: A Critical Review. | Materials (Basel) | 2026 | https://conductscience.org/library/papers/42882581 | PubMed |
| 42846679 | From Core Facility to Collaborative Partner: Reimagining Institutional Shared Resources as CRO-Model Research Partners Enhanced by Agentic AI. | J Biomol Tech | 2026 | https://conductscience.org/library/papers/42846679 | PubMed |
| 42842063 | Correspondence to: AdipoRon promotes angiogenesis in B-cell leukemia by modulating pro-angiogenic factors through AdipoR1. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42842063 | PubMed |
| 42811190 | Reproducibility in biomedical research. | Nat Med | 2026 | https://conductscience.org/library/papers/42811190 | PubMed |
| 42804443 | From preclinical promise to regulatory reality: translation of small rodent acute injury therapies to human approval and safety outcomes: A systematic review. | PLoS One | 2026 | https://conductscience.org/library/papers/42804443 | PubMed |
| 42786286 | Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42786286 | PubMed |
| 42786165 | Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42786165 | PubMed |
| 42737805 | Multi-Target Antitumor Effects of Natural Products and Approved Drug Repurposing in Non-Small Cell Lung Cancer: Advances in Mechanisms, Combination Regimens, Delivery System Optimization, and Clinical Challenges. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737805 | PubMed |
| 42728931 | Exploratory Insights into Barriers and Open Practices for Computational Reproducibility in Scientific Research. | F1000Res | 2025 | https://conductscience.org/library/papers/42728931 | PubMed |
| 42718899 | From bench to bedside: Overcoming translational hurdles in nanoparticle research with pharmacokinetic modeling. | Bioeng Transl Med | 2026 | https://conductscience.org/library/papers/42718899 | PubMed |
| 42711723 | Three-dimensional spheroid models in breast cancer: tumor microenvironment complexity, cancer stem cell-driven resistance, and translational model integration. | J Transl Med | 2026 | https://conductscience.org/library/papers/42711723 | PubMed |
| 42671246 | Cross-tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer's disease. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42671246 | PubMed |
| 42577796 | Stop comparing spells: a defense of mechanistic reasoning in quantitative medicine. | Front Digit Health | 2026 | https://conductscience.org/library/papers/42577796 | PubMed |
| 42576973 | Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure. | NAM J | 2026 | https://conductscience.org/library/papers/42576973 | PubMed |
| 42543391 | Pharmacological evolution of natural product-based and chemically engineered autophagy-modulating strategies in neurodegenerative diseases: a bibliometric mapping analysis (2006-2025). | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42543391 | PubMed |
| 42528866 | Commentary: Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities. | Front Immunol | 2026 | https://conductscience.org/library/papers/42528866 | PubMed |
| 42520002 | A survey of researchers' attitudes to preregistration in animal research reveals multiple perceived barriers to adoption. | PLoS Biol | 2026 | https://conductscience.org/library/papers/42520002 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22460880
GET https://conductscience.org/api/papers/v1/22460880/cited_by?page=2